CONSTANT LEVERAGE SHORT - MODERNA | Market Closed - Euronext Paris 17:30:02 15/05/2024 BST | ||
| 0.663 EUR | +4.41% |
|
| Current month | -44.80% | ||
| 1 month | -55.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 15/05/24 | 0.663 | +4.41% |
| 14/05/24 | 0.635 | -14.77% |
| 13/05/24 | 0.745 | -13.57% |
| 10/05/24 | 0.862 | +14.78% |
| 09/05/24 | 0.751 | -6.82% |
Real-time Euronext Paris
Last update May 15, 2024 at 05:30 pm
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| BQ8HB | |
| ISIN | FRBNPP04MJ78 |
| Date issued | 08/08/2022 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 5 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.6 € |
|---|---|
| Lowest since issue | 0.622 € |
| Spread | 0.005 € |
| Spread % | 0.75% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
129.1
USD
Average target price
138.5
USD
Spread / Average Target
+7.32%
- Stock Market
- Certificates
- BQ8HB Certificat
